IL-13 Antibody (F-6): sc-390676

IL-13 Antibody (F-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects IL-13 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IL-13 (F-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Interleukin-13, or IL-13, is a pleiotropic cytokine that plays a crucial role in immune regulation and inflammation, exhibiting approximately 30% sequence identity with IL-4 and sharing many biological activities. IL-13 is primarily secreted by activated T lymphocytes and has significant effects on monocytes, macrophages, and B cells, including the upregulation of CD23 and major histocompatibility complex proteins while downregulating CD14 expression. Notably, IL-13 is involved in the inhibition of proinflammatory cytokines and chemokines from activated monocytes, as well as the stimulation of immunoglobulin E expression on activated B cells, making IL-13 a key player in allergic responses and asthma. IL-13′s structure includes five cysteine residues that are essential for stability and function, as these residues form disulfide bonds critical for maintaining three-dimensional conformation. Additionally, IL-13 contains multiple N-linked glycosylation sites, which are important for biological activity and interaction with receptors. IL-13′s cDNA encodes a 131 amino acid precursor that includes a 20 amino acid signal peptide, which is cleaved to produce the mature, biologically active protein.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-13 Antibody (F-6) References:

1. Signal transduction of IL-13 and its role in the pathogenesis of bronchial asthma.  |  Izuhara, K. and Arima, K. 2004. Drug News Perspect. 17: 91-8. PMID: 15098062
2. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.  |  Jakubzick, C., et al. 2004. Immunol Res. 30: 339-49. PMID: 15531774
3. IL-4 and IL-13 dual antagonism: a promising approach to the dilemma of generating effective asthma biotherapeutics.  |  Borish, L. 2010. Am J Respir Crit Care Med. 181: 769-70. PMID: 20382798
4. Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis.  |  Chen, P., et al. 2015. Tumour Biol. 36: 121-7. PMID: 25472582
5. Effects of IL-13 on TGF-β and MMP-1 in periodontitis.  |  Beklen, A. 2017. Biotech Histochem. 92: 374-380. PMID: 28682139
6. IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma.  |  Berlow, NE., et al. 2018. PLoS One. 13: e0193565. PMID: 29621254
7. Common and different roles of IL-4 and IL-13 in skin allergy and clinical implications.  |  Roesner, LM., et al. 2019. Curr Opin Allergy Clin Immunol. 19: 319-327. PMID: 31157635
8. Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes.  |  Ulzii, D., et al. 2019. Int J Mol Sci. 20: PMID: 31284553
9. IL-4/IL-13 upregulates Sonic hedgehog expression to induce allergic airway epithelial remodeling.  |  Wang, X., et al. 2020. Am J Physiol Lung Cell Mol Physiol. 318: L888-L899. PMID: 32130032
10. IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice.  |  Hahn, L., et al. 2020. Cells. 9: PMID: 32846954

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IL-13 Antibody (F-6) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-IL-13 Antibody (F-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IL-13 Antibody (F-6) Specifications

Alternate Product Name: IL-13

Product Clone Name: F-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 104-132

Epitope Target: IL-13

Epitope Species: human

Product Reactivity/Detection: IL-13

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for IL-13 Antibody (F-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin

The preferred IL-13 antibody is IL-13 Antibody (A-9): sc-393365.